ESG

August 15, 2024 Alnylam Named a Humankind 100 Company for the 3rd Year in a Row Alnylam has been named to the HumanKind 100 list for the 2nd year in a row and we’re pleased to have moved up in the rankings from #97 in 2022 to #76 in 2023. Read More ›
May 7, 2024 Alnylam Publishes 2023 Corporate Responsibility Report Alnylam's 2023 Corporate Responsibility Report details our corporate responsibility and ESG efforts and progress. Read More ›
December 6, 2023 Alnylam Named One of America's Most Responsible Companies by Newsweek for 2nd Year in a Ro ... Alnylam has been named one of America's Most Responsible Companies by Newsweek for the 2nd year in a row. Read More ›
May 3, 2023 Building a Corporate Responsibility Program from the Ground Up: Key Learnings from Alnylam ... If you are building your program or assessing your program, here are five key learnings which may be helpful to your organization Read More ›
December 8, 2022 Alnylam Named One of America's Most Responsible Companies by Newsweek Alnylam has been named one of America's Most Responsible Companies for 2023 by Newsweek and research firm Statista Read More ›
October 13, 2021 Alnylam Challengers - a Health Equity Community Impact Program Alnylam Challengers is Alnylam's signature CSR Community Impact Program. It aims to improve health access to underserved communities. Read More ›

You are now leaving Alnylam.com

The following content may not be associated with Alnylam Pharmaceuticals.

Links to all outside sites are provided as a reference for our visitors.

Alnylam Pharmaceuticals does not endorse and is not responsible for the content on sites that are not owned and operated by Alnylam Pharmaceuticals.

Proceed to Site